XIAP deficiency syndrome in humans

Area of Science:

• Immunology
• Genetics
• Molecular Biology

Background:

• X-linked inhibitor of apoptosis (XIAP) deficiency, also known as X-linked lymphoproliferative syndrome type 2 (XLP-2), is a rare primary immunodeficiency.
• XIAP deficiency presents with a triad of hemophagocytic lymphohistiocytosis (HLH), splenomegaly, and inflammatory bowel disease (IBD), often resembling Crohn's disease.
• XIAP is recognized as a genetic cause of inherited IBD and plays roles beyond apoptosis, including innate immunity and inflammation regulation.

Purpose of the Study:

• To review the clinical manifestations of XIAP deficiency.
• To elucidate the molecular etiology and immunopathogenesis of XLP-2.
• To discuss recent advancements in understanding XIAP's function and its relation to XLP-2 pathophysiology.

Main Methods:

• Literature review of clinical cases and molecular studies.
• Analysis of XIAP's role in apoptosis, innate immunity, and inflammation.
• Synthesis of current research on XLP-2 pathogenesis.

Main Results:

• XIAP deficiency is characterized by susceptibility to EBV-triggered HLH, splenomegaly, and IBD.
• XIAP's function extends to regulating innate immunity and suppressing inflammation.
• Understanding XIAP's multifaceted roles is crucial for XLP-2 pathophysiology.

Conclusions:

• XIAP deficiency is a significant genetic disorder with severe clinical consequences.
• XIAP's anti-apoptotic and immunomodulatory functions are central to XLP-2.
• Further research into XIAP's mechanisms will advance treatment strategies for XLP-2 and related inflammatory conditions.